Tolerance Through Mixed Chimerism (Sip-Tego) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tolerance Through Mixed Chimerism (Sip-Tego) — Stella

Recruiting

Back to Kidney Failure trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

Massachusetts General Hospital, Boston, Massachusetts

Key details

Phase

Very early testing

Sponsor

Tatsuo Kawai, MD, PhD

Collaborators

Eledon Pharmaceuticals, ITB-Med LLC

Enrollment target

~12 participants

Started

May 2025

Primary completion

December 2030

Age range

18 Years – 65 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov